Literature DB >> 29089436

Protease-Mediated Suppression of DRG Neuron Excitability by Commensal Bacteria.

Jessica L Sessenwein1, Corey C Baker1, Sabindra Pradhananga1, Megan E Maitland1, Elaine O Petrof1, Emma Allen-Vercoe2, Curtis Noordhof1, David E Reed1, Stephen J Vanner1, Alan E Lomax3.   

Abstract

Peripheral pain signaling reflects a balance of pronociceptive and antinociceptive influences; the contribution by the gastrointestinal microbiota to this balance has received little attention. Disorders, such as inflammatory bowel disease and irritable bowel syndrome, are associated with exaggerated visceral nociceptive actions that may involve altered microbial signaling, particularly given the evidence for bacterial dysbiosis. Thus, we tested whether a community of commensal gastrointestinal bacteria derived from a healthy human donor (microbial ecosystem therapeutics; MET-1) can affect the excitability of male mouse DRG neurons. MET-1 reduced the excitability of DRG neurons by significantly increasing rheobase, decreasing responses to capsaicin (2 μm) and reducing action potential discharge from colonic afferent nerves. The increase in rheobase was accompanied by an increase in the amplitude of voltage-gated K+ currents. A mixture of bacterial protease inhibitors abrogated the effect of MET-1 effects on DRG neuron rheobase. A serine protease inhibitor but not inhibitors of cysteine proteases, acid proteases, metalloproteases, or aminopeptidases abolished the effects of MET-1. The serine protease cathepsin G recapitulated the effects of MET-1 on DRG neurons. Inhibition of protease-activated receptor-4 (PAR-4), but not PAR-2, blocked the effects of MET-1. Furthermore, Faecalibacterium prausnitzii recapitulated the effects of MET-1 on excitability of DRG neurons. We conclude that serine proteases derived from commensal bacteria can directly impact the excitability of DRG neurons, through PAR-4 activation. The ability of microbiota-neuronal interactions to modulate afferent signaling suggests that therapies that induce or correct microbial dysbiosis may impact visceral pain.SIGNIFICANCE STATEMENT Commercially available probiotics have the potential to modify visceral pain. Here we show that secretory products from gastrointestinal microbiota derived from a human donor signal to DRG neurons. Their secretory products contain serine proteases that suppress excitability via activation of protease-activated receptor-4. Moreover, from this community of commensal microbes, Faecalibacterium prausnitzii strain 16-6-I 40 fastidious anaerobe agar had the greatest effect. Our study suggests that therapies that induce or correct microbial dysbiosis may affect the excitability of primary afferent neurons, many of which are nociceptive. Furthermore, identification of the bacterial strains capable of suppressing sensory neuron excitability, and their mechanisms of action, may allow therapeutic relief for patients with gastrointestinal diseases associated with pain.
Copyright © 2017 the authors 0270-6474/17/3711758-11$15.00/0.

Entities:  

Keywords:  electrophysiology; inflammatory bowel disease; intestinal bacteria; nerve-gut interactions; neurogastroenterology

Mesh:

Substances:

Year:  2017        PMID: 29089436      PMCID: PMC5707769          DOI: 10.1523/JNEUROSCI.1672-17.2017

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  63 in total

Review 1.  Protease-activated receptors: how proteases signal to cells to cause inflammation and pain.

Authors:  Nigel W Bunnett
Journal:  Semin Thromb Hemost       Date:  2006-04       Impact factor: 4.180

2.  Probiotic Lactobacillus reuteri alleviates the response to gastric distension in rats.

Authors:  Swantje C Duncker; Takeshi Kamiya; Lu Wang; Pingchang Yang; John Bienenstock
Journal:  J Nutr       Date:  2011-08-31       Impact factor: 4.798

Review 3.  More than a gut feeling: the microbiota regulates neurodevelopment and behavior.

Authors:  John F Cryan; Timothy G Dinan
Journal:  Neuropsychopharmacology       Date:  2015-01       Impact factor: 7.853

Review 4.  The role of protease-activated receptor type 2 in nociceptive signaling and pain.

Authors:  P Mrozkova; J Palecek; D Spicarova
Journal:  Physiol Res       Date:  2016-04-12       Impact factor: 1.881

Review 5.  The joint-gut axis in inflammatory bowel diseases.

Authors:  Lianne K P M Brakenhoff; Désirée M van der Heijde; Daniel W Hommes; Tom W J Huizinga; Herma H Fidder
Journal:  J Crohns Colitis       Date:  2009-11-30       Impact factor: 9.071

6.  Role for protease activity in visceral pain in irritable bowel syndrome.

Authors:  Nicolas Cenac; Christopher N Andrews; Marinella Holzhausen; Kevin Chapman; Graeme Cottrell; Patricia Andrade-Gordon; Martin Steinhoff; Giovanni Barbara; Paul Beck; Nigel W Bunnett; Keith A Sharkey; Jose Geraldo P Ferraz; Eldon Shaffer; Nathalie Vergnolle
Journal:  J Clin Invest       Date:  2007-02-15       Impact factor: 14.808

7.  Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors.

Authors:  Christel Rousseaux; Xavier Thuru; Agathe Gelot; Nicolas Barnich; Christel Neut; Laurent Dubuquoy; Caroline Dubuquoy; Emilie Merour; Karen Geboes; Mathias Chamaillard; Arthur Ouwehand; Greg Leyer; Didier Carcano; Jean-Frédéric Colombel; Denis Ardid; Pierre Desreumaux
Journal:  Nat Med       Date:  2006-12-10       Impact factor: 53.440

8.  Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease.

Authors:  Ben Willing; Jonas Halfvarson; Johan Dicksved; Magnus Rosenquist; Gunnar Järnerot; Lars Engstrand; Curt Tysk; Janet K Jansson
Journal:  Inflamm Bowel Dis       Date:  2009-05       Impact factor: 5.325

9.  Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model.

Authors:  Rebeca Martín; Sylvie Miquel; Florian Chain; Jane M Natividad; Jennifer Jury; Jun Lu; Harry Sokol; Vassilia Theodorou; Premysl Bercik; Elena F Verdu; Philippe Langella; Luis G Bermúdez-Humarán
Journal:  BMC Microbiol       Date:  2015-03-21       Impact factor: 3.605

10.  Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut.

Authors:  Elaine O Petrof; Gregory B Gloor; Stephen J Vanner; Scott J Weese; David Carter; Michelle C Daigneault; Eric M Brown; Kathleen Schroeter; Emma Allen-Vercoe
Journal:  Microbiome       Date:  2013-01-09       Impact factor: 14.650

View more
  16 in total

Review 1.  Microbiota: a novel regulator of pain.

Authors:  Manon Defaye; Sandie Gervason; Christophe Altier; Jean-Yves Berthon; Denis Ardid; Edith Filaire; Frédéric Antonio Carvalho
Journal:  J Neural Transm (Vienna)       Date:  2019-09-24       Impact factor: 3.575

2.  Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS.

Authors:  Shoko Edogawa; Adam L Edwinson; Stephanie A Peters; Lakshmikanth L Chikkamenahalli; Wendy Sundt; Sara Graves; Sakteesh V Gurunathan; Margaret Breen-Lyles; Stephen Johnson; Roy Dyer; Rondell Graham; Jun Chen; Purna Kashyap; Gianrico Farrugia; Madhusudan Grover
Journal:  Gut       Date:  2019-03-28       Impact factor: 23.059

3.  Enhancement by TNF-α of TTX-resistant NaV current in muscle sensory neurons after femoral artery occlusion.

Authors:  Qin Li; Lu Qin; Jianhua Li
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-02-26       Impact factor: 3.619

4.  Bladder infection with uropathogenic Escherichia coli increases the excitability of afferent neurons.

Authors:  Nicolas Montalbetti; Marianela G Dalghi; Sheldon I Bastacky; Dennis R Clayton; Wily G Ruiz; Gerard Apodaca; Marcelo D Carattino
Journal:  Am J Physiol Renal Physiol       Date:  2021-11-15

5.  Genetic deletion of platelet PAR4 results in reduced thrombosis and impaired hemostatic plug stability.

Authors:  Robert H Lee; Tomohiro Kawano; Steven P Grover; Vanthana Bharathi; David Martinez; Dale O Cowley; Nigel Mackman; Wolfgang Bergmeier; Silvio Antoniak
Journal:  J Thromb Haemost       Date:  2021-11-10       Impact factor: 5.824

6.  Cannabinoid 1 and mu-Opioid Receptor Agonists Synergistically Inhibit Abdominal Pain and Lack Side Effects in Mice.

Authors:  Yang Yu; Quentin K Tsang; Josue Jaramillo-Polanco; Alan E Lomax; Stephen J Vanner; David E Reed
Journal:  J Neurosci       Date:  2022-07-05       Impact factor: 6.709

Review 7.  Metabolomics: The Key to Unraveling the Role of the Microbiome in Visceral Pain Neurotransmission.

Authors:  Adam Shute; Dominique G Bihan; Ian A Lewis; Yasmin Nasser
Journal:  Front Neurosci       Date:  2022-06-23       Impact factor: 5.152

Review 8.  The enteric nervous system in gastrointestinal disease etiology.

Authors:  Amy Marie Holland; Ana Carina Bon-Frauches; Daniel Keszthelyi; Veerle Melotte; Werend Boesmans
Journal:  Cell Mol Life Sci       Date:  2021-03-26       Impact factor: 9.261

9.  ATR regulates neuronal activity by modulating presynaptic firing.

Authors:  Murat Kirtay; Josefine Sell; Christian Marx; Holger Haselmann; Mihai Ceanga; Zhong-Wei Zhou; Vahid Rahmati; Joanna Kirkpatrick; Katrin Buder; Paulius Grigaravicius; Alessandro Ori; Christian Geis; Zhao-Qi Wang
Journal:  Nat Commun       Date:  2021-07-01       Impact factor: 14.919

10.  Colitis-Induced Microbial Perturbation Promotes Postinflammatory Visceral Hypersensitivity.

Authors:  Nicolas Esquerre; Lilian Basso; Manon Defaye; Fernando A Vicentini; Nina Cluny; Dominique Bihan; Simon A Hirota; Alana Schick; Humberto B Jijon; Ian A Lewis; Markus B Geuking; Keith A Sharkey; Christophe Altier; Yasmin Nasser
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2020-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.